Heron Therapeuti (HRTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Heron Therapeuti (HRTX) has a cash flow conversion efficiency ratio of -0.169x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.54 Million) by net assets ($9.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Heron Therapeuti balance sheet independence to measure how much of total assets are equity-financed.
Heron Therapeuti - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Heron Therapeuti's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Heron Therapeuti earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Heron Therapeuti Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heron Therapeuti ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Data Communications Management Ltd
TO:DCM
|
0.347x |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
-0.001x |
|
Tunas Alfin Tbk
JK:TALF
|
0.034x |
|
Matrimony.Com Limited
NSE:MATRIMONY
|
0.117x |
|
Immunoprecise Antibodies Ltd
NASDAQ:IPA
|
-0.048x |
|
TMT Steel Public Company Limited
BK:TMT
|
0.160x |
|
Caturkarda Depo Bangunan PT Tbk
JK:DEPO
|
0.013x |
|
TMT Investments PLC
LSE:TMT
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Heron Therapeuti (1989–2025)
The table below shows the annual cash flow conversion efficiency of Heron Therapeuti from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Heron Therapeuti.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $14.33 Million | $-27.59 Million | -1.925x | -387.53% |
| 2024-12-31 | $-33.65 Million | $-22.53 Million | 0.669x | -61.31% |
| 2023-12-31 | $-33.97 Million | $-58.79 Million | 1.730x | +115.99% |
| 2022-12-31 | $13.57 Million | $-146.91 Million | -10.825x | -312.91% |
| 2021-12-31 | $77.57 Million | $-203.35 Million | -2.622x | -235.45% |
| 2020-12-31 | $236.49 Million | $-184.82 Million | -0.782x | -153.33% |
| 2019-12-31 | $403.83 Million | $-124.58 Million | -0.308x | +40.46% |
| 2018-12-31 | $370.16 Million | $-191.81 Million | -0.518x | +60.10% |
| 2017-12-31 | $131.14 Million | $-170.30 Million | -1.299x | -120.58% |
| 2016-12-31 | $-21.25 Million | $-134.10 Million | 6.310x | +1049.10% |
| 2015-12-31 | $118.11 Million | $-78.53 Million | -0.665x | +30.45% |
| 2014-12-31 | $63.06 Million | $-60.28 Million | -0.956x | -61.68% |
| 2013-12-31 | $68.94 Million | $-40.76 Million | -0.591x | -80.12% |
| 2012-12-31 | $51.82 Million | $-17.01 Million | -0.328x | +33.03% |
| 2011-12-31 | $15.75 Million | $-7.72 Million | -0.490x | +88.24% |
| 2010-12-31 | $1.32 Million | $-5.48 Million | -4.166x | -157.43% |
| 2009-12-31 | $6.80 Million | $-11.00 Million | -1.618x | +49.34% |
| 2008-12-31 | $7.60 Million | $-24.27 Million | -3.195x | -444.92% |
| 2007-12-31 | $29.47 Million | $-17.28 Million | -0.586x | -177.01% |
| 2006-12-31 | $12.06 Million | $9.18 Million | 0.761x | +162.74% |
| 2005-12-31 | $6.20 Million | $-7.53 Million | -1.213x | -121.81% |
| 2004-12-31 | $14.15 Million | $-7.74 Million | -0.547x | +5.57% |
| 2003-12-31 | $11.26 Million | $-6.53 Million | -0.579x | -74.54% |
| 2002-12-31 | $15.46 Million | $-5.13 Million | -0.332x | +1.97% |
| 2001-12-31 | $19.17 Million | $-6.49 Million | -0.339x | -129.91% |
| 2000-12-31 | $21.16 Million | $-3.12 Million | -0.147x | -194.53% |
| 1999-12-31 | $12.00 Million | $-600.00K | -0.050x | +51.67% |
| 1998-12-31 | $14.50 Million | $-1.50 Million | -0.103x | -427.59% |
| 1997-12-31 | $10.20 Million | $-200.00K | -0.020x | +98.39% |
| 1996-12-31 | $5.00 Million | $-6.10 Million | -1.220x | +25.36% |
| 1995-12-31 | $5.20 Million | $-8.50 Million | -1.635x | -124.28% |
| 1994-12-31 | $11.80 Million | $-8.60 Million | -0.729x | +34.59% |
| 1993-12-31 | $10.50 Million | $-11.70 Million | -1.114x | -477.14% |
| 1992-12-31 | $20.20 Million | $-3.90 Million | -0.193x | +83.74% |
| 1991-12-31 | $3.20 Million | $-3.80 Million | -1.188x | -120.04% |
| 1990-12-31 | $6.30 Million | $-3.40 Million | -0.540x | -34.92% |
| 1989-12-31 | $9.50 Million | $-3.80 Million | -0.400x | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more